Harvest One

A World Class Cannabis Company

This Harvest One profile is part of a paid investor education campaign.*


Harvest One (TSXV:HVT) is a global cannabis company focused on delivering high-quality, innovative health and wellness cannabis products and technology to regulated markets around the world. Shareholders have significant exposure to the entire cannabis value chain through four wholly-owned subsidiaries: United Greeneries Ltd., Satipharm AG, Dream Water and Delivra. The company also has a 20 percent interest in Burb Cannabis Inc., a British Columbian-based cannabis retailer.

United Greeneries is a licensed producer under the Cannabis Act with a highly experienced cultivation team. Harvest One has also received its sales license for the United Greeneries brand. The company is building large-scale operations to meet the demand from both the medical market and the emerging Canadian recreational cannabis market.

Harvest One has also acquired an initial 52 percent interest in Greenbelt Greenhouse Ltd., a cannabis cultivation company with a 152,000-square-foot facility in Hamilton, Ontario. Once licensed, Greenbelt Greenhouse is expected to provide Harvest One with up to 15,000 kilograms of flower annually, ensuring a steady supply of cannabis for the company’s expanding health, wellness and self-care product lines. Greenbelt also has a 42,000-square-foot headhouse, an ideal location for a future extraction and processing lab.

Satipharm is a health and well-being company specializing in the development and manufacturing of cannabinoid-based products. The company’s CBD Gelpell® capsules have been sold across various countries in Europe and Australia. Satipharm has recently launched a lemon and lime-flavored CBD oil in Europe.

Harvest One recently signed a supply agreement with Health House International Pty Ltd. Harvest One’s Satipharm CBD Gelpell® capsules are expected to be distributed through Health House’s network of pharmacies as the company expands its distribution into Australia, New Zealand and Asia. The company has also submitted an Immigration Application to Health Canada so that the Satipharm capsules can be sold under the United Greeneries sales license.

To bolster its health and wellness portfolio, Harvest One acquired Delivra Corp. (TSXV:DVA), a specialty biotechnology company with a proprietary transdermal delivery system platform. The company has a strong intellectual property (IP) portfolio comprised of seven patent-pending applications and four patents.

Delivra also manufactures and sells a leading line of over-the-counter topicals and creams under the brand LivRelief™. LivRelief™ products are available in approximately 6,000 retail locations through a network of distribution partners, including Shoppers Drug Mart, Rexall, London Drugs and Walmart (NYSE:WMT), among others. CBD formulations of LivRelief™ are already underway.

As part of its initiative to become a vertically-integrated operation, Harvest One acquired Dream Water Global, a company that sells all-natural sleep shots and powders that promote relaxation and good sleep habits. Harvest One is already developing CBD formulations of Dream Water to sell where jurisdictions allow.

To further the development of Harvest One’s product lines, the company has signed a two-year supply agreement with GenCanna Global USA for CBD-based oils and finished products. Harvest One intends to market these products under its Dream Water, Satipharm and LivRelief™ brands. GenCanna is also expected to help Harvest One in the research, development and formulation of existing and new CBD-infused products.

To further its vertical integration, Harvest invested in Burb, a cannabis product retailer based in British Columbia, to obtain a 20 percent interest in the company. Burb intends to open eight stores throughout British Columbia and has plans to acquire retail locations in rural and urban areas in Alberta, Manitoba, Saskatchewan and Ontario.

Harvest One’s Company Highlights

  • The Canadian cannabis market is expected to generate up to $7.17 billion in sales in 2019.
  • Shareholders have significant exposure to both the medical and recreational cannabis markets, in Canada and globally, through three distinct brands.
  • United Greeneries, a Canadian licensed producer, is Harvest One’s cultivation arm for medical and recreational purposes.
  • Currently selling product in four provinces with established supply agreements; British Columbia, Saskatchewan, Manitoba and Ontario.
  • The Duncan facility has a current production capacity of approximately 1,000 kilograms per year and is currently undergoing an expansion to increase capacity to 3,500 kilograms per year.
  • Capacity target of 20,000 kilograms for 2020 to be achieved through Duncan expansion, completion of construction on Lucky Lake facility and additional supply agreements.
  • Growth strategy includes expanding current production capacity and negotiating potential acquisitions.
  • 398-acre plot of land acquired for a potential outdoor growing operation.
  • Satipharm, specializing in the development and manufacturing of cannabis-based health products, in Harvest One’s medical and health brand.
  • Supply agreement signed with Health House for Satipharm product distribution.
  • Satipharm is expanding sales across the EU and in Australia as well as preparing for its CBD Gelpell® capsules to be imported into Canada.
  • Supply agreement in place with GenCanna
  • Dream Water, the number one selling natural, 2.5-ounce, zero-calorie, liquid sleep shot with CBD formulations underway.
  • Acquisition of Delivra provides Harvest One with access to Canada’s top-selling topical cream products and a proprietary transdermal delivery system platform, with CBD formulations underway.
  • 20 percent interest in Burb with the option of acquiring a 51 percent interest.
  • Burb intends to expand into Alberta, Saskatchewan, Manitoba and Ontario.
  • Significant insider holding of 30 percent of shares.

The Canadian Cannabis Market

The Canadian cannabis market is expected to generate up to $7.17 billion in total sales in 2019. The market is expected to keep growing as more research is conducted into the health benefits the plant could potentially offer consumers. This trend is being backed by doctors, those wishing to self-medicate and those looking at integrating cannabis into their daily lives. In 2017, the global health and wellness sector reached $4.2 trillion and Harvest One intends to introduce its wellness products and brands into that industry.

United Greeneries: Positioned for Growth in the Recreational Markets

United Greeneries owns and operates a production facility in Duncan on Vancouver Island in British Columbia. It is also currently developing two additional sites, one in Lucky Lake, Saskatchewan and a greenhouse (Greenbelt) in Ontario.

Duncan Facility

The Duncan facility is a licensed medical cannabis producer with a current production capacity of 900 kilograms per year. The state-of-the-art 16,000-square-foot facility houses an automated high-tech growing system and a full in-house biochemical QA/QC lab. United Greeneries was granted a seed import permit in November 2016, its sales license in 2017 and its dealer’s license in June 2018.

United Greeneries commenced production at Duncan in December 2016 and is cultivating 31 distinct commercial varieties of cannabis.

Expansion plans for the facility include doubling the size of the building, including a 16,000-square foot propagation facility and advanced extraction capabilities. The new square footage will also include an R&D laboratory as well as packaging and processing capabilities.

Lucky Lake Facility

United Greeneries’ Lucky Lake facility is advancing through the final stages of the ACMPR licensing application process. Located in Lucky Lake, Saskatchewan, the modern 68,000-square foot agricultural facility sits on 23 acres of land and has a potential production capacity of 11,000 kilograms per year. The facility is also supported by transportation access and ample water and power supplies.

Stevens Green cannabis genetics supply agreement

United Greeneries signed a supply agreement with Health Canada licensed cultivator Stevens Green. Under the agreement, United Greeneries is expected to supply Stevens Green with clones of premium strains produced at its Duncan facility, along with proprietary cultivation techniques and expertise. The Stevens Green team plans to cultivate, harvest and supply a minimum of 2,000 kilograms of premium craft flower per year for three years with an option for renewal with an increase in the minimum production level to 5,000 kilograms per year. The premium craft flower produced by Stevens Green is intended for distribution under United Greeneries’ established Royal High and Captain’s Choice brands in the adult market.

Greenbelt Greenhouses: Cannabis Cultivation for Harvest One’s Brands

Harvest One has acquired an initial 52 percent interest in Greenbelt Greenhouses Ltd., a private company based in Hamilton, Ontario. Greenbelt is currently awaiting its standard cultivation and standard processing licenses from Health Canada.

Greenbelt cultivates high-quality cannabis in its 152,000-square-foot facility in Hamilton, Ontario. Greenbelt also has a 42,000-square-foot headhouse, an ideal location for a future extraction and processing lab. Once licensed, Greenbelt is expected to provide Harvest One with up to 15,000 kilograms of flower annually, ensuring a steady supply of cannabis for the company’s expanding health, wellness and self-care product lines.

With the acquisition of Greenbelt, Harvest One now has the ability to control the production of new infused formulations for its existing brands as well as to expand the company’s extraction capabilities for infused products. As the company expands its product lines, Greenbelt is able to provide additional cannabis supply without further significant capital investment.

“We are excited to acquire a majority interest in Greenbelt which significantly increases Harvest One’s cannabis supply, as we continue our formulations on cannabinoid-infused health, wellness and self-care products across our house of brands,” said Harvest One CEO Grant Froese. “In addition to the exceptional greenhouse facility, this acquisition also gives Harvest One space to build out its own extraction capabilities upon licensing which fulfills our goal of vertical integration from cultivation, to processing, extraction and, ultimately, premium infused products.”

Satipharm: Cannabis-based Health Products for Global Markets

Developing cutting-edge technology and pharmaceutical-grade cannabis products for the medical and health-based cannabis markets.

Satipharm believes the commercialization of its signature Gelpell® technology for cannabinoid products could transform the company into a global leader in the medical and health-based cannabis industry. The Gelpell® delivery technology helps address bioavailability and consistency issues associated with the delivery of orally-ingested cannabis-based products. Production of 10 milligram and 50 milligram Gelpell® microgel capsules began in May 2015 and since then, the company has also obtained the pharmaceutical central numbers (PZN codes) for these. Satipharm capsules are currently sold throughout the EU, where the capsules and oils are available online, on Amazon (NASDAQ:AMZN), in mail-order pharmacies and in brick-and-mortar establishments such as Holland & Barrett.

Satipharm has recently expanded its product portfolio to include a CBD oil. The lemon and lime-flavored CBD oil is specifically formulated to address three major consumer concerns: taste, GMP certification and reliable dosing. The product is now available online at www.satipharm.com and at brick and mortar locations throughout Europe.

The Satipharm capsules have also been made available to prescribed users in Australia, following a September 2017 final approval of compliance. The company has also submitted an import application to Health Canada so that Satipharm capsules can be sold under United Greeneries’ ACMPR license.

Satipharm is dedicated to growing its portfolio of delivery technology IP with further expansion plans targeting the introduction of other formulations including THC.

As part of an agreement in which Satipharm has sublicensed the pharmaceutical application of the Gelpell® process to PhytoTech Therapeutics Limited (PTL), PTL has completed to phases of clinical trials on the product. The first, tested on 14 patients, demonstrated the safety and tolerability of Satipharm alongside a lack of significant side effects. It also showed a perfect proportionality between the company’s CBD 10 milligrams and CBD 100 milligrams products. The results of this phase of testing were published in an international medical journal.

The second phase of clinical trials evaluated the safety, tolerability and efficacy of oral administration of Satipharm CBD capsules as an adjunctive treatment to 15 children (ages two to 15) with treatment-resistant epilepsy. To date, Harvest One has released the results for its first 10 patients. These showed that Satipharm CBD capsules reduced monthly seizure frequency when added to the patient’s existing medications and that the drug’s safety profile remained consistent with Phase 1 results. The median reduction of seizures was 79.5 percent in the 12-week treatment period.

PhytoTech Therapeutics Acquisition

Subsequent to the sublicensing agreement, Harvest One and MMJ PhytoTech Limited (ASX:MMJ) jointly acquired PTL in November 2018. Under the terms of the agreement, Satipharm will be gaining access to PTL’s advanced patents in favorable jurisdictions. Harvest One intends to use the patents to further its R&D and product development in regards to the cannabis oils market.

Health House supply agreement

Harvest One has signed a supply agreement with Health House, a renowned medical cannabis wholesale and distribution company. Under the terms of the agreement, Harvest One will supply Health House with Satipharm CBD 50 milligram tablets, which are expected to be distributed through Health House’s network of pharmacies. Health House will also provide healthcare professionals with Satipharm product information. Satipharm products are expected to be available in Australia as Harvest One expands its distribution into New Zealand and legal markets in Asia.

“This agreement with Health House increases the availability of our Satipharm CBD 50mg Gelpell® capsules across Australia, while expanding Satipharm’s medical cannabis distribution territories to New Zealand and Asia where and when legal,” said Froese. “We are committed to delivering the highest quality cannabinoid-based products globally. As further regions become available, we will endeavor to put agreements in place that will allow us to meet the needs of our patients.”

Holland & Barrett distribution agreement

Satipharm signed an agreement with Holland & Barrett, Europe’s largest retailer of nutritional supplements and wellness products, for the distribution of Satipharm’s CBD 10 milligram Gelpell®. Under the agreement, the products are available for sale at 841 Holland Barrett stores and online via the Holland & Barrett website.

“This supply agreement is pivotal to our global strategy. Having a European health and wellness leader like Holland & Barrett trust and carry our product shows the investment in our manufacturing standards and commercial strategy is proving to be a success” said Froese. “We plan to build on this valued agreement by growing the demand for Satipharm CBD Gelpell® capsules through both instore and online activity.”

Dream Water

In May 2018, Harvest One completed the acquisition of Dream Water Products Canada Inc. and Sarpes Beverages LLC (Dream Water USA), which have jointly become Dream Water Global. Dream Water sells beverages and powders that promote relaxation and support restful sleep across North America in over 30,000 outlets.

Harvest One’s strategy for the company is to scale its existing e-commerce and retail operations and launch Dream Water’s product innovation pipeline. The company also plans to develop the brand within the cannabis space, producing product lines that include cannabidiol (CBD) or full-spectrum hemp and can be sold under federally regulated markets.

The company has signed supply agreements with major retailers such as Walmart US and Kroger (NYSE:KR). This adds to the agreements already in place with Shoppers Drug Mart, Loblaws, Circle K, Canadian Tire (TSX:CTC) and Amazon among others across North America. Dream Water has also received its NSF International Certified for Sport® designation. The designation allows sports clubs and organizations, such as the MLB, NHL and CFL clubs, among others, to recommend Dream Water to their players.


In July 2019, Harvest One completed the acquisition of Delivra, a specialty biotechnology company with a proprietary transdermal delivery system platform. Delivra has a strong intellectual property (IP) portfolio comprised of seven patent-pending applications and four patents. The company is developing a portfolio of pharma-based products for healing diabetic wounds, inflammatory diseases and cannabis-based therapeutics.

The DelivraTM platform delivers pharmaceutical and natural molecules through the skin in a targeted manner. The platform converts plant-based and GMP-certified synthetic drugs into liquid crystals and a polymeric water-oil emulsion to ensure the stability of the product over its lifecycle. Delivra has demonstrated the commercial success of the system for the treatment of localized pathologies, such as limb pain, varicose veins and wound healing products.

harvest one delivra skin graphic

Delivra also manufactures and sells a growing line of over-the-counter topicals and creams under the brand LivReliefTM. LiveReliefTM is Canada’s number one selling natural nerve pain relief cream. Delivra has developed several formulations for the treatment of sleep and anxiety that are currently available for purchase.

The company has developed an additional 30 over the counter and cannabis-based products that are ready to market once regulations are passed. These products include a veterinary product line that will feature Meloxicam, anti-inflammatory and topical analgesics. LivRelief products are available in approximately 6,000 retail locations through a network of distribution partners, including Shoppers Drug Mart, Rexall, London Drugs and Walmart among others.

Burb Cannabis: Harvest One’s Retail Strategy

Harvest One has obtained a 20 percent interest in Burb Cannabis Corp., a cannabis retailer in British Columbia that is committed to servicing communities outside of busy metropolitan centers. Harvest One retains the right to increase its interest in the company to 51 percent.

Burb intends to open eight stores throughout British Columbia and has plans to acquire retail locations in rural and urban areas in Alberta, Manitoba, Saskatchewan and Ontario. The roll-out will include a mix of corporate-owned, franchise and joint venture stores.

“Moving into brick and mortar is familiar territory for me and an extremely valuable opportunity for Harvest One,” said Froese. “Harvest One is committed to providing consumers with high-quality, end-to-end cannabis solutions and investing in Burb helps us achieve this goal. The investment in Burb also allows Harvest One to play a pro-active role in educating consumers about recreational cannabis and shape the future of cannabis retail in Canada.”

Harvest One’s Agreements

Provincial Supply Agreements

Harvest One has signed supply agreements with four provinces in Canada, giving the company access to a variety of markets in the large nation. In Ontario, the company has been engaged by the Ontario Cannabis Retail Corporation to supply its Royal High-branded products for online sale through the Ontario Cannabis Store and through private retailers.

In Manitoba, the company has a supply agreement in place with the Manitoba Liquor and Lotteries, under which United Greeneries has committed to supplying high-quality, craft cannabis for adult use. United Greeneries also entered into a supply agreement with the British Columbia Liquor Distribution Board, whereby the company supplies recreational cannabis. Finally, Harvest One also has been selected as a registered supplier of cannabis with the Saskatchewan Liquor and Gaming Authority.

Valens Extractions Agreements

In November 2018, Harvest One entered into a multi-year extraction services agreement with Valens GroWorks Corp. (CSE:VGW,OTC:MYMSF) for cannabis extraction and value-added services.

Under the terms of the agreements, Harvest One’s subsidiary, United Greeneries, will ship bulk quantities of dried cannabis for an initial period of three years and then Valens will process it into bulk resin and other cannabis oil derived products on a fee-for-service-basis. Additionally, Valens will also conduct R&D to expand Harvest One’s product lines, including health and wellness products, beverages, vape pens and nutraceuticals.

“This agreement with Valens represents a valuable opportunity to accelerate Harvest One’s product development strategy,” said Froese. “We are excited to leverage Valens’ industry-leading expertise to further expand our recreational and health and wellness products under United Greeneries, Satipharm and Dream Water. Furthermore, this partnership gives Harvest One the ability to diversify our medical product offerings to better serve our patients.”

TruTrace Agreement

In February 2019, Harvest One announced that it was utilizing TruTrace Technologies Inc. (CSE:TTT,OTC:TTTSF) proprietary genome tracking software to collect and register its cannabis plant DNA and strains. Harvest One’s participation in TruTrace’s master genome strain and clone registration program is expected to allow the company to show that its medical cannabis strains come as labeled, providing increased transparency to its products.

“TruTrace’s technology is intended to enable us to guarantee that our strain origins and content are exactly as labeled, providing medical consumers with a level of certainty they could not expect with similar, unverified products,” said Froese. “This increased level of quality control is in keeping with our mission to build a global house of brands, providing lifestyle and wellness health products to consumers and patients in regulated markets.”

In August 2019, Harvest One and TruTrace, in conjunction with Shoppers Drug Mart, completed phase one of a pilot program designed to increase the transparency and validation of products within the medical cannabis industry. The pilot program utilized TruTrace’s StrainSecureTM technology as a master registry for standardized testing, product verification and quality assurance.

Shoppers Drug Mart announced that United Greeneries was able to meet all of the requirements of phase one due in part to the subsidiary’s early adoption of the StrainSecureTM platform and implementation of the master genome strain and clone registration program. Phase two is expected to run until late November, followed by full production and implementation.

Shoppers Drug Mart

Through its subsidiary, United Greeneries, Harvest One became a medical cannabis supplier for Shoppers Drug Mart in March 2019. Under the terms of the agreement, Harvest One will supply Shoppers Drug Mart with Satipharm-branded medical cannabis products which will be sold online. Soon after signing the agreement, Harvest One completed its first shipment of products to Shoppers Drug Mart.

“We are incredibly proud to be working with Shoppers Drug Mart to supply them with our premium, indoor-grown cannabis under the Satipharm health and wellness brand,” said Froese. “We see this supply agreement as a further step towards fulfilling our vision of being a vertically-integrated house of brands in the cannabis health, wellness and self-care sector.”

GenCanna Global USA Agreement

Under an initial two-year agreement, GenCanna is expected to supply Harvest One with GMP-certified CBD oil and finished products for distribution in regulated markets in the US, Europe and around the globe. The products are expected to be distributed under the Dream Water, Satipharm and LivRelief™ brands. GenCanna is also expected to help Harvest One in the research, development and formulation of existing and new CBD-infused products.

“Working with world-class partners like GenCanna to supply premium quality, traceable, consistent ingredients, all from GMP-certified facilities, is critical to our core strategy at Harvest One to only offer consumers best-in-class premium products, with consistent and predictable effects, in delivery formats they have come to understand and demand,” said Froese.

The agreement with GenCanna ensures that Harvest One has a consistent supply of premium-quality hemp-derived CBD for infusion into the company’s Dream Water, Satipharm and LivRelief™ products. With Harvest One’s vast distribution network, the company is dedicated to advancing its goal of being a leading house of brands in the health, wellness and self-care sectors.

3 Sixty Secure

Harvest One has selected 3 Sixty Secure Corp. (CSE:SAFE) to provide secure transport and retail delivery, as well as cannabis storage services for the company.

Harvest One’s Management Team

Grant Froese—CEO and Director

Grant Froese joins Harvest One following a 38-year career with Canadian retail giant Loblaw Companies Limited, last serving as Chief Operating Officer. During his career at Loblaw, he led operations and merchandising at all levels and has had oversight of information technology, supply chain, digital and e-commerce businesses, marketing and Loblaw’s industry-leading control brands. Froese has also been appointed to the Board of Directors.

Andrew Kain – COO

Andrew Kain is a lawyer by profession with almost 25 years of extensive corporate, financial and legal experience. For 15 years, he was General Counsel to a US$5+ billion global hedge fund that operated a proprietary quantitative trading platform and managed a US$2+ billion fund of funds portfolio, where he worked with investment banks, brokerage houses, exchanges and regulatory bodies in capital markets around the globe.

Most recently, he was in private practice providing general corporate, financial and advisory services to start-up and early-stage companies in emerging industries. He is also a founder and President of Windular Research and Technologies Inc., a privately held corporation that provides innovative renewable energy systems, consulting and advisory services to the global telecommunications industry.

Aaron Wong — CFO

Aaron Wong is a Chartered Professional Accountant with over 15 years of finance leadership experience in public and private organizations including Seaspan Corporation, Teekay Corporation and CHC Helicopter. He has been with Harvest One since December 2017, serving as Corporate Controller.

Andy Bayfield – CCO

Andy Bayfield comes to Harvest One to continue a successful career which has focused on consumer packaged goods with internationally recognized companies such as Cadbury, Coca-Cola, and Canada Dry Mott’s, a division of Keurig Dr Pepper. Mr. Bayfield has a proven track record of leading sales transformation, accelerating product innovation, and defining routes to market internationally. His focus on commercial execution and innovative brand strategies has driven consistent growth across many consumer-loved brands throughout his career.

Nick Maltchev — CTO

Nick Maltchev is a global executive with a passion for results and building great teams. He brings a mix of strategic thinking and deep technical knowledge and over 25 years of technology experience. He has been involved with the industry since 2004 and was an integral part of the Advanced Nutrients management team over a period of 12 years, holding several positions including information technology manager, COO and general manager. He holds a BBA degree, as well as other designations in project management, cybersecurity and computer science. He is also currently in the process of finishing an MBA in management information systems.

Deb Milimaka Miles — Chief Administrative Officer and Chief People Officer

Utilizing her extensive experience gained from previous senior HR executive positions at Loblaw and SMART Technologies, as well as in the financial sector, Deb Milimaka Miles plays a key role in the overall company strategy from an organizational, culture and vision point of view. As CAO and CPO she is responsible for managing the administration and integration of people and culture for Harvest One, its subsidiaries and multiple brands as they expand across Canada and around the world. Her depth of experience in transforming teams, driving process efficiencies, and integrating cultures across acquisitions will allow Harvest One to execute on its strategy to become an industry-leading global health and wellness company.

Will Stewart – Senior VP Corporate and Public Affairs

Will Stewart is a well-known Canadian cannabis executive, insider and former Harvest One board member. He is a leading influencer in cannabis and worked for years in political and corporate circles pushing for legalization and to reduce stigma. He was named a Top 100 Lobbyist in Canada for seven consecutive years and received the Queen’s Diamond Jubilee Medal for contributions to Canadian public policy. In addition, Stewart has consulted with over 12 cannabis companies and was recently the Vice President of another vertically-integrated cannabis company.

Jonathon Hartshorn – President of Satipharm

Jonathan holds a degree in Pharmacology and Physiology and is a Fellow of the Institute of Chartered Accountants. He has over 15 years of experience in the Life Sciences arena, including Discovery, Development, Clinical Trials and OTC and grocery retail experience, as well as transaction experience including M&A and financings. He has held key leadership positions in Pfizer Consumer Healthcare Ireland, McNeil Healthcare and Venn Life Sciences Plc.

Frank Holler — Chairman

Frank Holler is President and CEO of Ponderosa Capital Inc., and is an expert in biotechnology, investment banking and venture capital. He previously served as CEO and Partner of Lions Capital Corp., fund manager for BC Advantage Funds and the Lions Funds; as President and CEO of Xenon Pharmaceuticals Inc., a private genomics-based drug development company; as President and CEO of ID Biomedical Corporation, a vaccine development company sold to GlaxoSmithKline plc; and as a founding director of Angiotech Pharmaceuticals, a TSX/ NASDAQ listed medical device company. Before working in biotechnology and healthcare, Holler was an Investment Banker with Merrill Lynch Canada and Wood Gundy Inc. (now CIBC World Markets).

Peter Wall — Director

Peter Wall is a corporate lawyer based in Perth, Australia and is a partner at one of Australia’s leading corporate and commercial law firms. He was a founding director and shareholder in Phytotech Medical Limited (now MMJ Phytotech Ltd.), the first medical cannabis company to list on the ASX.

Jason Bednar — Director

Jason Bednar is a Chartered Accountant with over 18 years of direct professional experience in the financial and regulatory management of companies listed on the TSX, TSXV, American stock exchanges and the ASX.

Dr. Joseph Gabriele – Director

Dr. Joseph Gabriele is the founder, inventor and visionary behind the Delivra™ technology. He has devoted the past 12 years to innovation, development and commercialization activities at Delivra. In addition to providing guidance and vision for Delivra, he actively stewards its robust R&D program. He has a doctorate in molecular pharmacology and is an Assistant Professor (PT), McMaster University, Department of Psychiatry and Behavioral Neurosciences, as well as Special Graduate Faculty, University of Guelph, Department of Biomedical Sciences.

Dr. Gabriele received a B.Sc. from the University of Toronto, with M.Sc. and Ph.D. degrees from McMaster University. His Ph.D. training was conducted under Dr. R.K. Mishra, focusing on molecular pharmacology and neuroscience and its implications in psychiatric and neurological disorders. He has received numerous awards, including the recipient of The Health Care EY Entrepreneur of the Year 2018 Award, a CIHR studentship award in pharmacology during his M.Sc. degree, an NSERC Canada Graduate Scholarship during his Ph.D. training and the International Congress on Schizophrenia Research Young Investigator Award.

*Disclaimer: This profile is sponsored by Harvest One (TSXV:HVT). This profile provides information which was sourced by the Investing News Network (INN) and approved by Harvest One, in order to help investors learn more about the company. Harvest One is a client of INN. The company’s campaign fees pay for INN to create and update this profile.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Harvest One and seek advice from a qualified investment advisor.